Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Debt (2016 - 2025)

Historic Total Debt for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $47.8 million.

  • Fortress Biotech's Total Debt fell 895.51% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 895.51%. This contributed to the annual value of $58.0 million for FY2024, which is 475.55% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Total Debt is $47.8 million, which was down 895.51% from $50.0 million recorded in Q2 2025.
  • Over the past 5 years, Fortress Biotech's Total Debt peaked at $91.7 million during Q4 2022, and registered a low of $42.6 million during Q3 2021.
  • Its 5-year average for Total Debt is $62.0 million, with a median of $56.4 million in 2025.
  • Per our database at Business Quant, Fortress Biotech's Total Debt surged by 11415.82% in 2022 and then plummeted by 4977.13% in 2023.
  • Fortress Biotech's Total Debt (Quarter) stood at $42.9 million in 2021, then soared by 113.64% to $91.7 million in 2022, then plummeted by 33.66% to $60.9 million in 2023, then dropped by 4.76% to $58.0 million in 2024, then fell by 17.58% to $47.8 million in 2025.
  • Its last three reported values are $47.8 million in Q3 2025, $50.0 million for Q2 2025, and $56.4 million during Q1 2025.